標(biāo)題: Titlebook: Resistance of Targeted Therapies Excluding Antibodies for Lymphomas; Andrés J. M. Ferreri Book 2018 Springer International Publishing AG, [打印本頁] 作者: Lampoon 時間: 2025-3-21 17:34
書目名稱Resistance of Targeted Therapies Excluding Antibodies for Lymphomas影響因子(影響力)
書目名稱Resistance of Targeted Therapies Excluding Antibodies for Lymphomas影響因子(影響力)學(xué)科排名
書目名稱Resistance of Targeted Therapies Excluding Antibodies for Lymphomas網(wǎng)絡(luò)公開度
書目名稱Resistance of Targeted Therapies Excluding Antibodies for Lymphomas網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Resistance of Targeted Therapies Excluding Antibodies for Lymphomas被引頻次
書目名稱Resistance of Targeted Therapies Excluding Antibodies for Lymphomas被引頻次學(xué)科排名
書目名稱Resistance of Targeted Therapies Excluding Antibodies for Lymphomas年度引用
書目名稱Resistance of Targeted Therapies Excluding Antibodies for Lymphomas年度引用學(xué)科排名
書目名稱Resistance of Targeted Therapies Excluding Antibodies for Lymphomas讀者反饋
書目名稱Resistance of Targeted Therapies Excluding Antibodies for Lymphomas讀者反饋學(xué)科排名
作者: LAST 時間: 2025-3-21 22:12 作者: INERT 時間: 2025-3-22 00:28 作者: ATP861 時間: 2025-3-22 07:30 作者: FLOAT 時間: 2025-3-22 09:01
Book 2018resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance..作者: 縮短 時間: 2025-3-22 13:52 作者: Preamble 時間: 2025-3-22 17:44 作者: Additive 時間: 2025-3-22 21:31
Proteasome Inhibitors with a Focus on Bortezomib, patients eventually have progressive disease and development resistance to treatment. Multiple unique mechanisms of resistance have been identified, and they are unified by reducing a cell’s sensitivity to endoplasmic reticulum stress either from changes intrinsic to the cancer cell or extrinsic to作者: Glucocorticoids 時間: 2025-3-23 03:09 作者: GROUP 時間: 2025-3-23 06:59
mTOR Inhibitors, with Special Focus on Temsirolimus and Similar Agents,Ks). Dysregulation of mTOR signaling is associated with the development of cancers, including myeloid and lymphoid malignancies. Here, we will provide a brief overview of mTOR inhibitors and discuss the results obtained using these compounds in hematologic malignancies and especially in lymphomas. M作者: 彎彎曲曲 時間: 2025-3-23 12:42 作者: FUSC 時間: 2025-3-23 17:15
Proteasome Inhibitors with a Focus on Bortezomib,ity to degrade unfolded proteins and plasmacytic differentiation to a more immature plasma cell phenotype with reduced immunoglobulin production. Understanding these mechanisms of resistance can inform therapeutic options to reverse drug resistance or use of novel combinations to synergistically target the unfolded protein response pathway.作者: 規(guī)章 時間: 2025-3-23 20:23 作者: Psychogenic 時間: 2025-3-23 23:17 作者: morale 時間: 2025-3-24 05:40 作者: DOSE 時間: 2025-3-24 08:13 作者: LAIR 時間: 2025-3-24 13:36
Pashtoon Murtaza Kasi,Grzegorsz S. Nowakowskiconformal class of Lorentz metrics on T/S by singling out the “squares” as null vectors. We observe that there is a complex structure on S which makes this Lie-bracket pairing the real part of a Hermitian pairing from S ? S → T/S ? C . Using this structure, it appears that one can give graded analog作者: Genome 時間: 2025-3-24 17:14 作者: aerial 時間: 2025-3-24 21:26
Linda M. Scottconformal class of Lorentz metrics on T/S by singling out the “squares” as null vectors. We observe that there is a complex structure on S which makes this Lie-bracket pairing the real part of a Hermitian pairing from S ? S → T/S ? C . Using this structure, it appears that one can give graded analog作者: 保全 時間: 2025-3-24 23:22 作者: Ointment 時間: 2025-3-25 06:17
BTK Inhibitors: Focus on Ibrutinib and Similar Agents, of treatment and they are detected at a later timepoint, suggesting the evolution of clonal dynamics under treatment pressure. Primary and secondary resistances in MCL are driven by mutations promoting the activation of the alternative NFκB-pathway and PI3K-AKT pathway. Further work needs to be don作者: Generator 時間: 2025-3-25 08:10 作者: 迎合 時間: 2025-3-25 13:35
Inhibitors of the JAK/STAT Pathway, with a Focus on Ruxolitinib and Similar Agents,or use in humans currently, whilst others are under evaluation in clinical trials, and more efficacious drugs are being developed. The nature and therapeutic potential of these compounds in the treatment of patients with lymphoma are discussed.作者: 彈藥 時間: 2025-3-25 17:10
Resistance of Targeted Therapies Excluding Antibodies for Lymphomas作者: Microaneurysm 時間: 2025-3-25 22:38 作者: 不安 時間: 2025-3-26 03:33
corresponding principal bundles. The most familiar are: the Lorentz group = 0(3,1,8) which uses the bundle of orthonormal frames, GL(4,R) with the general linear frame bundle, the Poincare group = IO(3,1,R) with the affine orthonormal frame bundle, and the spinor group, SL(2,C), with the orthonormal作者: mydriatic 時間: 2025-3-26 05:14
Mattias Mattsson,Lydia Scarfòcorresponding principal bundles. The most familiar are: the Lorentz group = 0(3,1,8) which uses the bundle of orthonormal frames, GL(4,R) with the general linear frame bundle, the Poincare group = IO(3,1,R) with the affine orthonormal frame bundle, and the spinor group, SL(2,C), with the orthonormal作者: 珊瑚 時間: 2025-3-26 10:52 作者: 隱士 時間: 2025-3-26 13:06
Kevin Barley,Samir Parekhcorresponding principal bundles. The most familiar are: the Lorentz group = 0(3,1,8) which uses the bundle of orthonormal frames, GL(4,R) with the general linear frame bundle, the Poincare group = IO(3,1,R) with the affine orthonormal frame bundle, and the spinor group, SL(2,C), with the orthonormal作者: Critical 時間: 2025-3-26 17:36
Pashtoon Murtaza Kasi,Grzegorsz S. Nowakowski(these are also defined by Kostant but we present a directly geometrical definition which is more convenient for our purposes), vector bundles, and principal bundles..With these notions in place, we can define a graded G-structure on a graded manifold In the simplest non-trivial case, this leads imm作者: aphasia 時間: 2025-3-26 21:52
Teresa Calimeri,Andrés J. M. Ferrericorresponding principal bundles. The most familiar are: the Lorentz group = 0(3,1,8) which uses the bundle of orthonormal frames, GL(4,R) with the general linear frame bundle, the Poincare group = IO(3,1,R) with the affine orthonormal frame bundle, and the spinor group, SL(2,C), with the orthonormal作者: 拋物線 時間: 2025-3-27 03:18 作者: 使殘廢 時間: 2025-3-27 07:31 作者: 考博 時間: 2025-3-27 09:36 作者: occult 時間: 2025-3-27 16:11 作者: Hiatal-Hernia 時間: 2025-3-27 19:34 作者: 舔食 時間: 2025-3-27 22:06
Resistance of Targeted Therapies Excluding Antibodies for Lymphomas978-3-319-75184-9Series ISSN 2196-5501 Series E-ISSN 2196-551X 作者: 符合規(guī)定 時間: 2025-3-28 02:07
Andrés J. M. FerreriThis book will focus on recently developed targeted therapies other than monoclonal antibodies used in lymphoma patients, both in routine practice and investigative trials.Divided by groups of drugs, 作者: 極端的正確性 時間: 2025-3-28 08:14 作者: 網(wǎng)絡(luò)添麻煩 時間: 2025-3-28 13:03
them separate headings increases the readability). Afterwards, a number of forces that must be considered are discussed (now with a regular font face). The next section begins with a bold face “Therefore” and contains the core of the solution. This may be followed by additional information about the
